FRANK D. LEE

Corporate Board Profile

Tech Score: 0/100

Bausch Health Companies Inc.

Filing Date	Source Excerpt
2024-04-04	Mr. Lee is the Chief Executive Officer and member of the Board of Pacira BioSciences, Inc., a publicly traded pharmaceutical company targeting non-opioid pain management and regenerative health solutions. Prior to joining Pacira, he served as Chief Executive Officer of Forma Therapeutics Inc., a publicly traded biopharmaceutical company focused on rare hematologic diseases and cancers, from March 2019 until its acquisition by Novo Nordisk in October 2022. During his tenure at Forma, Mr. Lee transformed the organization from an early-stage drug discovery company into one focused on the clinical development of lead assets in rare hematologic disorders and cancer. Prior to Forma, Mr. Lee served as Senior Vice President, Global Product Strategy and Therapeutic Area Head for Immunology, Ophthalmology and Infectious Diseases at Genentech, Inc., a member of the Roche Group. Mr. Lee’s 13-year tenure at Genentech included leadership positions of increasing scope and responsibility focused on delivering transformative medicines to patients and driving the growth of multiple in oncology, immunology and ophthalmology products to blockbuster/multi-blockbuster status. Prior to Genentech, Mr. Lee spent approximately 13 years across Novartis, Janssen and Eli Lilly. He received a Bachelor of Science degree in Chemical Engineering from Vanderbilt University and an MBA from the Wharton Graduate School of Business. Mr. Lee has served as director of Bolt Biotherapeutics, a publicly traded biotechnology company targeting immunotherapies, since November 2021, and an as Advisor to Lightstone Ventures, a venture capital firm focused on medical devices and biopharmaceuticals, since January 2023. Stock Ownership: 0 Common Shares — $ 0; 0 RSUs. Total Equity Value at Risk: $0 representing 0% of the Company’s current aggregate amount of $500,000 required under the share ownership guidelines for non-employee Directors and 0% of the annual Board retainer. Subject to his election, Mr. Lee has until May 14, 2029 to achieve the expected minimum equity ownership under such share ownership guidelines. The Board has determined that Mr. Lee’s extensive experience in the pharmaceutical industry is a valuable contribution to the Board. In addition, his global experience and strong track record of product development and commercial success across both small biotech and large pharmaceutical organizations qualify Mr. Lee as a member of the Board and the committees on which he is expected to serve.
2025-04-02	Mr. Lee is the Chief Executive Officer and member of the Board of Pacira BioSciences, Inc. ... Committees: Science & Technology Committee, Talent & Compensation Committee. ... Director Compensation Table shows total compensation of $330,750.

Filing Date

Source Excerpt

2024-04-04

Mr. Lee is the Chief Executive Officer and member of the Board of Pacira BioSciences, Inc., a publicly traded pharmaceutical company targeting non-opioid pain management and regenerative health solutions. Prior to joining Pacira, he served as Chief Executive Officer of Forma Therapeutics Inc., a publicly traded biopharmaceutical company focused on rare hematologic diseases and cancers, from March 2019 until its acquisition by Novo Nordisk in October 2022. During his tenure at Forma, Mr. Lee transformed the organization from an early-stage drug discovery company into one focused on the clinical development of lead assets in rare hematologic disorders and cancer. Prior to Forma, Mr. Lee served as Senior Vice President, Global Product Strategy and Therapeutic Area Head for Immunology, Ophthalmology and Infectious Diseases at Genentech, Inc., a member of the Roche Group. Mr. Lee’s 13-year tenure at Genentech included leadership positions of increasing scope and responsibility focused on delivering transformative medicines to patients and driving the growth of multiple in oncology, immunology and ophthalmology products to blockbuster/multi-blockbuster status. Prior to Genentech, Mr. Lee spent approximately 13 years across Novartis, Janssen and Eli Lilly. He received a Bachelor of Science degree in Chemical Engineering from Vanderbilt University and an MBA from the Wharton Graduate School of Business. Mr. Lee has served as director of Bolt Biotherapeutics, a publicly traded biotechnology company targeting immunotherapies, since November 2021, and an as Advisor to Lightstone Ventures, a venture capital firm focused on medical devices and biopharmaceuticals, since January 2023. Stock Ownership: 0 Common Shares — $ 0; 0 RSUs. Total Equity Value at Risk: $0 representing 0% of the Company’s current aggregate amount of $500,000 required under the share ownership guidelines for non-employee Directors and 0% of the annual Board retainer. Subject to his election, Mr. Lee has until May 14, 2029 to achieve the expected minimum equity ownership under such share ownership guidelines. The Board has determined that Mr. Lee’s extensive experience in the pharmaceutical industry is a valuable contribution to the Board. In addition, his global experience and strong track record of product development and commercial success across both small biotech and large pharmaceutical organizations qualify Mr. Lee as a member of the Board and the committees on which he is expected to serve.

2025-04-02

Mr. Lee is the Chief Executive Officer and member of the Board of Pacira BioSciences, Inc. ... Committees: Science & Technology Committee, Talent & Compensation Committee. ... Director Compensation Table shows total compensation of $330,750.

Data sourced from SEC filings. Last updated: 2026-02-03